JP6266659B2 - 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 - Google Patents
癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 Download PDFInfo
- Publication number
- JP6266659B2 JP6266659B2 JP2015560283A JP2015560283A JP6266659B2 JP 6266659 B2 JP6266659 B2 JP 6266659B2 JP 2015560283 A JP2015560283 A JP 2015560283A JP 2015560283 A JP2015560283 A JP 2015560283A JP 6266659 B2 JP6266659 B2 JP 6266659B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- compound
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MANSWCXFKVIKPE-HIJQLYNKSA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(N)=O)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(N)=O)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O)(=O)=O MANSWCXFKVIKPE-HIJQLYNKSA-N 0.000 description 1
- BEBAQWUEVUWBRD-RTIGCHDFSA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)C(/C=C(\C(\Cl)=C/C)/F)=C)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)C(/C=C(\C(\Cl)=C/C)/F)=C)C1=O)(=O)=O BEBAQWUEVUWBRD-RTIGCHDFSA-N 0.000 description 1
- QGOICCMBEDDFCI-NXQGQTBASA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)c(cc2F)ccc2Cl)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)c(cc2F)ccc2Cl)C1=O)(=O)=O QGOICCMBEDDFCI-NXQGQTBASA-N 0.000 description 1
- IHUMWHKQAVMWCV-HXZUPTHJSA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(O)=O)c2cc(Cl)ccc2)c(cc2F)ccc2Cl)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(O)=O)c2cc(Cl)ccc2)c(cc2F)ccc2Cl)C1=O)(=O)=O IHUMWHKQAVMWCV-HXZUPTHJSA-N 0.000 description 1
- JEGRBRICAOMWLN-LCQQBMRFSA-N CC(C)(C)SC[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC=C)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O Chemical compound CC(C)(C)SC[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC=C)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O JEGRBRICAOMWLN-LCQQBMRFSA-N 0.000 description 1
- UPKBNWFSKZKMBB-UHFFFAOYSA-N CC(CC(C(c(cc1F)ccc1Cl)=O)c1cc(Cl)ccc1)C(OC)=O Chemical compound CC(CC(C(c(cc1F)ccc1Cl)=O)c1cc(Cl)ccc1)C(OC)=O UPKBNWFSKZKMBB-UHFFFAOYSA-N 0.000 description 1
- ZVXWVVRTWLVZKV-UHFFFAOYSA-N COC(c(cc1F)ccc1Cl)=O Chemical compound COC(c(cc1F)ccc1Cl)=O ZVXWVVRTWLVZKV-UHFFFAOYSA-N 0.000 description 1
- QNQSZYRUBCVBEK-JECHBYEQSA-N C[C@@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cc(Cl)ccc2)C1=O Chemical compound C[C@@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cc(Cl)ccc2)C1=O QNQSZYRUBCVBEK-JECHBYEQSA-N 0.000 description 1
- QBWGADZCVCWHEF-LQYCBEJQSA-N C[C@@](C[C@H](c1cccc(Cl)c1)O)(CC=C)C(N[C@H](CO)C(C1)[C@@H]1c(c(C)c1)cc(Cl)c1F)=O Chemical compound C[C@@](C[C@H](c1cccc(Cl)c1)O)(CC=C)C(N[C@H](CO)C(C1)[C@@H]1c(c(C)c1)cc(Cl)c1F)=O QBWGADZCVCWHEF-LQYCBEJQSA-N 0.000 description 1
- QNQSZYRUBCVBEK-LQAWEQHXSA-N C[C@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cccc(Cl)c2)C1=O Chemical compound C[C@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cccc(Cl)c2)C1=O QNQSZYRUBCVBEK-LQAWEQHXSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770901P | 2013-02-28 | 2013-02-28 | |
| US61/770,901 | 2013-02-28 | ||
| PCT/US2014/018759 WO2014134201A1 (en) | 2013-02-28 | 2014-02-26 | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510028A JP2016510028A (ja) | 2016-04-04 |
| JP2016510028A5 JP2016510028A5 (enExample) | 2017-02-23 |
| JP6266659B2 true JP6266659B2 (ja) | 2018-01-24 |
Family
ID=50272765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560283A Active JP6266659B2 (ja) | 2013-02-28 | 2014-02-26 | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8952036B2 (enExample) |
| EP (1) | EP2961735B1 (enExample) |
| JP (1) | JP6266659B2 (enExample) |
| CN (1) | CN105121407B (enExample) |
| AR (1) | AR094970A1 (enExample) |
| AU (1) | AU2014223547B2 (enExample) |
| CA (1) | CA2902856C (enExample) |
| MX (1) | MX368703B (enExample) |
| TW (1) | TW201505630A (enExample) |
| UY (1) | UY35353A (enExample) |
| WO (1) | WO2014134201A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
| US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| BR112016010564A2 (pt) | 2013-11-11 | 2017-10-10 | Amgen Inc | terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US9962380B2 (en) * | 2015-09-23 | 2018-05-08 | Wisconsin Alumni Research Foundation | Methods for treating cognitive deficits associated with fragile X syndrome |
| SG11201808728QA (en) * | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| KR20180132861A (ko) * | 2016-04-12 | 2018-12-12 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bet 단백질 분해제 |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| IL319432A (en) * | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| MX2020012503A (es) * | 2018-05-25 | 2021-08-11 | Kartos Therapeutics Inc | Métodos de tratamiento de neoplasias mieloproliferativas. |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| WO2022056368A1 (en) | 2020-09-14 | 2022-03-17 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1016828A (en) | 1961-11-13 | 1966-01-12 | Mcneilab Inc | Substituted morpholines and process for preparing same |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| WO1996006095A1 (en) | 1994-08-19 | 1996-02-29 | Abbott Laboratories | Endothelin antagonists |
| PT885215E (pt) | 1996-02-13 | 2006-08-31 | Abbott Lab | Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| TR200000993T2 (tr) | 1997-08-04 | 2000-12-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU1910299A (en) | 1997-12-18 | 1999-07-05 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| JP2004518688A (ja) | 2001-01-30 | 2004-06-24 | ブリストル−マイヤーズ スクイブ カンパニー | ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法 |
| ATE409181T1 (de) | 2001-05-08 | 2008-10-15 | Univ Yale | Proteomimetische verbindungen und verfahren |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| PL370823A1 (en) | 2001-12-18 | 2005-05-30 | F.Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| JP4814228B2 (ja) | 2004-05-18 | 2011-11-16 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ｃｉｓ−イミダゾリン |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| CA2599476A1 (en) | 2005-03-16 | 2006-09-21 | F. Hoffmann-La Roche Ag | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments |
| AU2006232517A1 (en) | 2005-04-04 | 2006-10-12 | Eisai R&D Management Co., Ltd. | Dihydropyridine compounds and compositions for headaches |
| JP4870778B2 (ja) | 2005-12-01 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ガン剤として使用されるｐ５３およびｍｄｍ２タンパク質間の相互作用の阻害剤としての２，４，５−トリフェニルイミダゾリン誘導体 |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| BRPI0713119A2 (pt) | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
| JP2009543865A (ja) | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド | ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤 |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| WO2008021338A2 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Tricyclic oxazolidone derivatives useful as pr modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| RU2487127C2 (ru) | 2007-10-09 | 2013-07-10 | Ф.Хоффманн-Ля Рош Аг | Хиральные цис-имидазолины |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| WO2009082038A2 (en) | 2007-12-26 | 2009-07-02 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| US20110105488A1 (en) | 2008-03-21 | 2011-05-05 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| MY160424A (en) | 2008-09-18 | 2017-03-15 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxyamides. |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| IN2012DN01693A (enExample) | 2009-08-26 | 2015-06-05 | Novartis Ag | |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US20120046306A1 (en) * | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
-
2014
- 2014-02-26 WO PCT/US2014/018759 patent/WO2014134201A1/en not_active Ceased
- 2014-02-26 AU AU2014223547A patent/AU2014223547B2/en active Active
- 2014-02-26 CA CA2902856A patent/CA2902856C/en active Active
- 2014-02-26 JP JP2015560283A patent/JP6266659B2/ja active Active
- 2014-02-26 CN CN201480011184.XA patent/CN105121407B/zh active Active
- 2014-02-26 EP EP14709849.5A patent/EP2961735B1/en active Active
- 2014-02-26 MX MX2015011245A patent/MX368703B/es active IP Right Grant
- 2014-02-27 UY UY0001035353A patent/UY35353A/es not_active Application Discontinuation
- 2014-02-27 TW TW103106905A patent/TW201505630A/zh unknown
- 2014-02-27 US US14/192,553 patent/US8952036B2/en active Active
- 2014-02-28 AR ARP140100685A patent/AR094970A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105121407A (zh) | 2015-12-02 |
| TW201505630A (zh) | 2015-02-16 |
| MX368703B (es) | 2019-10-11 |
| US8952036B2 (en) | 2015-02-10 |
| AU2014223547B2 (en) | 2017-11-16 |
| WO2014134201A1 (en) | 2014-09-04 |
| CA2902856A1 (en) | 2014-09-04 |
| AU2014223547A1 (en) | 2015-09-03 |
| JP2016510028A (ja) | 2016-04-04 |
| CA2902856C (en) | 2021-02-16 |
| EP2961735B1 (en) | 2017-09-27 |
| AR094970A1 (es) | 2015-09-09 |
| EP2961735A1 (en) | 2016-01-06 |
| CN105121407B (zh) | 2017-07-18 |
| US20140243372A1 (en) | 2014-08-28 |
| UY35353A (es) | 2014-09-30 |
| MX2015011245A (es) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6266659B2 (ja) | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 | |
| EP2576510B1 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| JP6377123B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 | |
| EP2376478B1 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| JP2023527891A (ja) | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 | |
| EP3790867B1 (en) | Kdm1a inhibitors for the treatment of disease | |
| JP6417338B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 | |
| EP2334683B1 (en) | Saturated bicyclic heterocyclic derivatives as smo antagonists | |
| TW201722914A (zh) | 醫藥化合物 | |
| JPWO2005103012A1 (ja) | ヒドラジノ複素環ニトリル化合物およびその用途 | |
| HK1215707B (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| HK1182711B (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171220 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6266659 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |